A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed 16 enrolled Benitec Biopharma, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.

Timeline

Start: 2018-03-15
Primary completion: 2018-12-12
Completion: 2020-04-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BB-401	Antisense oligonucleotide	1.92 ug/ml	Other

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications